LTX-315 (trifluoroacetate salt) |
رقم الكتالوجGC48989
One-Click Copy Product Info
|
A synthetic cationic amphiphilic peptide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LTX-315 is a synthetic cationic amphiphilic peptide.1 It is cytotoxic to a variety of human cancer cell lines, including A20 lymphoma and AT-84 squamous cell carcinoma cells (IC50s = 8.3 and 11 µM, respectively), and to non-cancerous MRC-5 fibroblasts (IC50 = 34.3 µM) but not human red blood cells (EC50 = >695 µM).2 LTX-315 is also cytotoxic to drug-sensitive and -resistant cancer cell lines (IC50s = 2.1-6.4 and 2.5-3.2 µM, respectively). It permeabilizes mitochondrial membranes and induces immunogenic cell death in tumor cells in vitro.3,1 Intratumoral administration of LTX-315 (1 mg peptide/50 µl saline) increases tumor levels of IL-1β and IL-6 and induces necrosis in, and complete regression of, tumors in a B16/F1 syngeneic mouse model of melanoma.4
1.Zhou, H., Forveille, S., Sauvat, A., et al.The oncolytic peptide LTX-315 triggers immunogenic cell deathCell Death Dis.7(3)e2134(2016) 2.Huag, B.E., Camilo, K.A., Eliassen, L.T., et al.Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptideJ. Med. Chem.59(7)2918-2927(2016) 3.Zhou, H., Forveille, S., Sauvat, A., et al.The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilizationOncotarget6(29)26599-26614(2015) 4.Camilo, K.A., Berge, G., Ravuri, C.S., et al.Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315Cancer Immunol. Immunother.63(6)601-613(2014)
| Cas No. | N/A | SDF | |
| Canonical SMILES | O=C([C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC([C@H](CC3=CNC4=CC=CC=C34)NC([C@@H](NC([C@@H](NC([C@H](CC5=CNC6=CC=CC=C65)NC([C@H](CC7=CNC8=CC=CC=C78)NC([C@@H](NC([C@H](CCCCN)N)=O)CCCCN)=O)=O)=O)CCCCN)=O)CCCCN)=O)=O)N[C@@H](CCCCN)C(N)=O.OC(C(F)(F)F)=O | ||
| Formula | C78H106N18O9·XCF3COOH | M.Wt | 1439.8 |
| الذوبان | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 1 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 694.5 μL | 3.4727 mL | 6.9454 mL |
| 5 mM | 138.9 μL | 694.5 μL | 1.3891 mL |
| 10 mM | 69.5 μL | 347.3 μL | 694.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)